IXHL Stock Analysis: Buy, Sell, or Hold?
IXHL - Incannex Healthcare Limited American Depositary Shares
$3.97
0.26 (7.01%)
▲
5d:
+24.06%
30d:
+30.16%
90d:
+34.12%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When IXHL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IXHL shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: IXHL shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IXHL is currently trading at $3.97, which is considered extended relative to its 30-day fair value range of $3.18 to $3.75. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.6) compared to its historical average (3.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, IXHL is in a strong uptrend. The price is approaching resistance at $3.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.0% recently.
Market Sentiment: IXHL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.63 (+344.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IXHL is in a strong uptrend. The price is approaching resistance at $3.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.0% recently.
Market Sentiment: IXHL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.63 (+344.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.18 -
$3.75
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range (+5.9% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.0%)
- BULLISH: Trading 344.1% below Wall St target ($17.63)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$3.18 -
$3.75
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.77
Resistance Level
$3.80
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.65
Wall Street Target
$17.63
(+344.1%)
Revenue Growth (YoY)
-100.0%
PE vs Historical
-1.7 vs 3.7
CHEAP
Share & Embed Analysis
Last updated: July 02, 2026 9:43 PM ET
Data refreshes hourly during market hours. Next update: 10:43 PM
Data refreshes hourly during market hours. Next update: 10:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IXHL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 63 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 54 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 60 HOLD |
